Given that defects in the antigen presentation machinery and IFNγ signaling contribute to acquired resistance to immune checkpoint inhibitors (ICIs) [8, 37, 38, 39], we used a TGCA dataset [28] (Table S7) to assess an association between ANGPTL2 mRNA levels and overall survival after treatment with programed cell death‐1 (PD‐1) inhibitors in patients with metastatic melanoma. The gene discussed is ANGPTL2; the disease is metastatic melanoma.